Article

Long-Acting Insulin Analogs Versus Human Insulins

Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, Department of Internal Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, Department of Pediatrics, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, Editor-in-Chief, Diabetes Technology & Therapeutics.
Diabetes Technology &amp Therapeutics (Impact Factor: 2.29). 11/2008; 10(5):331-2. DOI: 10.1089/dia.2008.0071
Source: PubMed
0 Followers
 · 
92 Views
 · 
0 Downloads
  • Source
    • "Insulin analogue is found to mitigate weight gain (see Haak et al. (2003), Haak et al. (2005), Hermansen & Davies (2007), Raslová et al. (2007), Russell-Jones & Khan (2007), Dornhorst et al. (2008), Demssie et al. (2009), Freeman (2009), Mandosi et al. (2009), Marre et al. (2009), Monami et al. (2009)). It may even cause weight loss of up to 1 kg (Russell-Jones (2007), Sreenan et al. (2008), Hermansen et al. (2009), for meta-analyses see Bush (2007), Raskin (2007), and Satish & Ramachandra (2008)). The evidence allows to associate insulin analogue with a weight gain of 0 kg, while the levels used in the DCE are + 2.5, 0, and -1 kg, respectively. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals interviewed in 2007, 200 suffered from type 1 diabetes, 150 from insulin-treated type 2 diabetes, and 150 from insulin-naive type 2 diabetes. The long-acting insulin analogue ”Insulin Detemir” is compared to human insulin as the status quo. The DCE contains two price attributes, copayment and increased contributions to health insurance. As one would expect, non-affected non-diabetics and insulin-naive diabetics exhibit higher willingness-to-pay (WTP) values through copayment (adjusted for probability of contracting diabetes), while affected type 1 and insulin-treated type 2 diabetics have higher WTP through increased contributions. However, WTP values exceed the extra treatment cost in both financing alternatives, justifying inclusion of the innovation in the benefit list from a cost-benefit point of view.
  • Source
    • "Insulin analogue is found to mitigate weight gain (see Haak et al. (2003), Haak et al. (2005), Hermansen & Davies (2007), Raslová et al. (2007), Russell-Jones & Khan (2007), Dornhorst et al. (2008), Demssie et al. (2009), Freeman (2009), Mandosi et al. (2009), Marre et al. (2009), Monami et al. (2009)). It may even cause weight loss of up to 1 kg (Russell-Jones (2007), Sreenan et al. (2008), Hermansen et al. (2009), for meta-analyses see Bush (2007), Raskin (2007), and Satish & Ramachandra (2008)). The evidence allows to associate insulin analogue with a weight gain of 0 kg, while the levels used in the DCE are + 2.5, 0, and -1 kg, respectively. "
  • [Show abstract] [Hide abstract]
    ABSTRACT: The new rDNA and DNA-derived "basal" insulin analogs, glargine and detemir, represent significant advancement in the treatment of diabetes compared with conventional NPH insulin. This review describes blood glucose homeostasis by insulin in people without diabetes and outlines the physiological application of exogenous insulin in patients with type 1 and type 2 diabetes. The requirements for optimal basal insulin treatment are discussed and the methods used in the evaluation of basal insulins are presented. An essential criterion in the development of an "ideal" basal insulin preparation is that the molecular modifications made to the human insulin molecule do not compromise safety. It is also necessary to obtain a clear understanding of the pharmacokinetic and pharmacodynamic characteristics of the two currently available basal insulin analogs. When comparing glargine and detemir, the different molar concentration ratios of the two insulin formulations should be considered along with the nonspecificity of assay systems used to determine insulin concentrations. However, euglycemic clamp studies in crossover study design provide a good basis for comparing the pharmacodynamic responses. When the latter is analyzed by results of intervention clinical trials, it is concluded that both glargine and detemir are superior to NPH in type 1 and type 2 diabetes. However, there is sufficient evidence to demonstrate that these two long-acting insulin analogs are different in both their pharmacokinetic and pharmacodynamic profiles. These differences should be taken into consideration when the individual analogs are introduced to provide basal insulin supplementation to optimize blood glucose control in patients with type 1 and type 2 diabetes as well. PubMed-Medline was searched for articles relating to pharmacokinetics and pharmacodynamics of glargine and detemir. Articles retrieved were reviewed and selected for inclusion if (1) the euglycemic clamp method was used with a duration >or=24 h, (2) a single subcutaneous dose of glargine/detemir was used, and (3) area under the curve for insulin concentrations or glucose infusion rates were calculated.
    Diabetes Technology &amp Therapeutics 11/2008; 10(5):333-49. DOI:10.1089/dia.2008.0023 · 2.29 Impact Factor
Show more